Please disable your Ad Blocker to better interact with this website.

Pharmaceutical giant Pfizer is set to earn $54 billion in profits in 2022 alone thanks to its line of coronavirus vaccines, according to reports.

The company says it expects to rake in $32 billion in revenue for the COVID vaccinations and an additional $22 billion in revenue from Paxlovid, their antiviral COVID-19 treatment pill, NTD reported.

The Big Pharma giant reported that its revenue nearly doubled to $81.3 billion last year, up from $41.6 billion in 2020 as the world continues to fall down the COVID rabbit hole.

The earnings report is based on contracts signed or close to being signed as of late January, Pfizer explained.

“The development of mRNA vaccines should have revolutionized the global COVID response. But we’ve let Pfizer withhold this essential medical innovation from much of the world, all while ripping off public health systems with an eye-watering mark-up,” said Tim Bierley of Global Justice Now, who accused Pfizer of behavior that is “nothing short of pandemic profiteering.”

“Right now, there are billions of people who cannot access COVID-19 vaccines and treatments. Many are in countries with the facilities needed to manufacture mRNA jabs, but Pfizer’s jealous guarding of its patent stands in the way. And we’re seeing thousands of preventable deaths each day as a result,” Bierley added.

“It has made more than enough money from this crisis,” Bierley said.

Follow Warner Todd Huston on Facebook at:


Warner Todd Huston

Warner Todd Huston has been writing editorials and news since 2001 but started his writing career penning articles about U.S. history back in the early 1990s. Huston has appeared on Fox News, Fox Business Network, CNN, and several local Chicago News programs to discuss the issues of the day. Additionally, he is a regular guest on radio programs from coast to coast. Huston has also been a Breitbart News contributor since 2009. Warner works out of the Chicago area, a place he calls a "target rich environment" for political news.


Join the conversation!

We have no tolerance for comments containing violence, racism, vulgarity, profanity, all caps, or discourteous behavior. Thank you for partnering with us to maintain a courteous and useful public environment where we can engage in reasonable discourse.


Need help, have a question, or a comment? Send us an email and we'll get back to you as soon as possible.


Log in with your credentials

Forgot your details?